Camurus Ab News - 0RD1

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire LUND, Sweden, March 26...

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence PR Newswire LUND, Sweden, March 26...

Swissmedic approves Buvidal for the treatment of opioid dependence

Swissmedic approves Buvidal for the treatment of opioid dependence PR Newswire LUND, Sweden, Dec. 18, 2020 LUND, Sweden, Dec. 18, 2020...

Swissmedic approves Buvidal for the treatment of opioid dependence

Swissmedic approves Buvidal for the treatment of opioid dependence PR Newswire LUND, Sweden, Dec. 18, 2020 LUND, Sweden, Dec. 18, 2020...

Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obe...

Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obesity PR...

Camurus Raises Full Year 2020 Revenue Guidance

Camurus Raises Full Year 2020 Revenue Guidance PR Newswire LUND, Sweden, June 23, 2020 LUND, Sweden, June 23, 2020 /PRNewswire/ -- Camurus today...

Camurus Raises Full Year 2020 Revenue Guidance

Camurus Raises Full Year 2020 Revenue Guidance PR Newswire LUND, Sweden, June 23, 2020 LUND, Sweden, June 23, 2020 /PRNewswire/ -- Camurus today...

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US PR Newswire LUND...

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US PR Newswire LUND...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Camurus Ab (0RD1)

Professional-Grade Tools, for Individual Investors.

0RD1 News

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence

Swissmedic approves Buvidal for the treatment of opioid dependence

Swissmedic approves Buvidal for the treatment of opioid dependence

Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obe...

Camurus Raises Full Year 2020 Revenue Guidance

Camurus Raises Full Year 2020 Revenue Guidance

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US

Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence

Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence

Camurus' Interim Report January-March 2020

Camurus' Interim Report January-March 2020

Camurus Announces Strong First Quarter Demand for Buvidal®

Camurus Announces Strong First Quarter Demand for Buvidal®

0RD1 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Camurus Ab (0RD1) News

Camurus Ab (0RD1)

Professional-Grade Tools, for Individual Investors.

0RD1 News

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence

Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence

Swissmedic approves Buvidal for the treatment of opioid dependence

Swissmedic approves Buvidal for the treatment of opioid dependence

Positive Results From Phase 2 Study of Once-weekly FluidCrystal® Formulation of Setmelanotide in Healthy Volunteers With Obe...

Camurus Raises Full Year 2020 Revenue Guidance

Camurus Raises Full Year 2020 Revenue Guidance

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US

Camurus Announces Submission of Request for Final Approval of Brixadi™ for the Treatment of Opioid Use Disorder in the US

Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence

Camurus' Buvidal® Reimbursed in Sweden for the Treatment of Opioid Dependence

Camurus' Interim Report January-March 2020

Camurus' Interim Report January-March 2020

Camurus Announces Strong First Quarter Demand for Buvidal®

Camurus Announces Strong First Quarter Demand for Buvidal®

0RD1 Discussion

Your Recent History